Orthopedic Medical Device Leader WanJie TianYuan Secures Over RMB 100 Million Strategic Investment from Elite Capital, WinX Capital Acts as Exclusive Financial Advisor

Shell Society (WeChat Official Account ID: iBio4P) learned that recently, Beijing Wanjie Medical Device Co., Ltd. ("Wanjie Medical"), a leading company in China's sports medicine industry, received an over 100-million-yuan strategic investment from Elite Capital. This marks another investment move by Elite Capital in China’s sports medicine field.WinX CapitalWinX Capital served as the exclusive financial advisor.

In recent years, with the improvement of living standards and fitness awareness among the Chinese people, the number of people participating in sports has significantly increased, along with a rise in sports-related injuries. Data from Global Market Insights shows that the global market size for sports medicine will exceed $9 billion by 2025, with an annual growth rate of nearly 8%, much higher than traditional orthopedics (2-3%) and orthopedic consumables (5%). In China, the growth rate of sports medicine is even more rapid. The industry's compound annual growth rate from 2020 to 2025 is expected to reach 23.4%, the highest among major global markets.

Currently, sports medicine in China is encountering a historic opportunity. Although domestic enterprises are still in the early stage of development, they have already possessed the capability to compete with foreign enterprises that dominate the market in terms of technology, and the wave of import substitution is on the rise.

Wanjie Medical is a national high-tech enterprise specializing in the research, production, and sales of high-value consumables in the fields of sports medicine and orthopedic repair. It is also currently the only company in China that has entered the orthopedic repair field from the sports medicine field.The funds raised this time will be mainly used for the research and development of products in the sports medicine and orthopedic repair industries, as well as to accelerate the commercialization of these products.

As the vice chairman unit of the China Sports Medicine Innovation Alliance, the company boasts an innovative R&D team led by renowned clinical experts and a doctoral and master's R&D team of "outstanding young talents," gathering a large number of R&D talents in the fields of polymer biomaterials, tissue engineering, machinery, and automation. This has formed a cross-disciplinary composite team with core expertise in design, materials, production, medicine, clinical practice, legal affairs, and marketing.

At the same time, in April this year, Wanjie Medical successfully obtained two Class III 《Medical Device Registration Certificates》 issued by the National Medical Products Administration. These 《Medical Device Registration Certificates》 cover two core products in the field of sports medicine: ligament fixation screws and suture anchors. The acquisition of these product registration certificates will help the company further expand its sports medicine product line business, enhance its comprehensive competitiveness, have a positive impact on the company's future operations, and further demonstrate Wanjie Medical's commitment to becoming a pioneer in the orthopedic niche and a leader in the field of sports medicine.

Mr. Jin Weilun, Founder of WinX Capital, stated: Wanjie Medical has deeply cultivated the sports medicine track, accumulating substantial expertise in both product development and sales, while also gaining support from several top experts in China's sports medicine industry. The sports medicine market in China is at the brink of an explosion, and investing ahead of the market’s widespread attention to the industry is a hallmark of WinX Capital’s investment strategy. Beyond just providing funding, we will assist Wanjie Medical in comprehensively upgrading its strategic planning, management operations, production optimization, and capital operations. We believe that within three years, the company has the potential to become the most competitively comprehensive leading enterprise in China's sports medicine field.

Ms. Zhang Mei, founder of Wanjie Medical, expressed: "We are very grateful for the strategic investment from investors such as Yilian Capital. Yilian Capital is a close partner to entrepreneurs and has provided comprehensive support to the company in many aspects, including capital planning, government relations, and key customers. At the same time, we thank our financial advisor, WinX Capital, for their dedication and professionalism."

Dr. Guowen Zou, founder of WinX Capital, stated: We are delighted to assist Wanjie Medical as its exclusive financial advisor, helping the company introduce strategic investor Yu Lian Capital. The Wanjie Medical team is very pragmatic, with a rich product portfolio, strong medical-engineering R&D capabilities, and mature marketing channels both domestically and internationally. We believe that Wanjie Medical will continue to lead the way in the golden track of sports medicine.

About Elite Capital

WinX Capital was established in 2009, adhering to the investment philosophy of "focusing on being the dedicated partner behind founders." It possesses deep industry resources and a professional team with extensive experience in capital operations. WinX Capital aims to build a private equity investment institution characterized by its deep cultivation of industries and integration of upstream and downstream industrial chains. With a focus on niche industry investments as an entry point, it concentrates on biotechnology, medical aesthetics, and the medical device industry, committing to long-term value investing. Leveraging its profound industry resources and a professional team with rich investment banking experience, WinX Capital assists companies in addressing challenges related to strategic development, market expansion, industrial chain resource integration, financing and mergers and acquisitions, and public offerings. This drives the long-term sustainable growth of enterprises, achieving shared growth between companies and investment institutions.

About WinX CapitalWinX Capital 

WinX Capital, a leading investment bank in China's healthcare sector. The founding team includes five global finance Ph.D.s from the PBC School of Finance at Tsinghua University, and the frontline team has an average of over 10 years of experience in management, investment, and M&A, with a total amount of investment and M&A exceeding 30 billion yuan. Headquartered in Beijing and Shanghai, covering more than 3,000 active investment institutions and industry groups. In 2020, it was ranked as one of the "WISE 2020 Top 5 Most Growth-Potential New Investment Banks in China" by 36Kr, and among the "Top 4 Best Financial Advisory Firms in the Healthcare Sector in 2020" by Qiming Technology & Xinsheng Chuangfu.